“…[13][14][15][16][17] The utility of shortterm devices, such the Medos, 18 Abiomed and Impella, has been shown in primary graft failure and post-cardiotomy, but the first 2 of these devices have significant risks of thromboembolism, bleeding and infection, raising the clinical cost. Moreover, the Abiomed BVS 500, the most widely used in this category, still has several limitations, including: pump-related complications (seal disruption); the patient's continued sedation and inability to ambulate; and a maximum achievable flow of 6 liters, which is sometimes not sufficient in septic patients.…”